Investors

Corporate Profile

Cingulate® (CTx®) is a Phase 3 clinical stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build and advance a pipeline of branded next-generation pharmaceutical products. These will be designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas, such as anxiety disorders, where PTR™ technology may be employed to develop future product candidates.

Computershare Welcome Letter

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

01 Apr 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023 $9.1 Million of Debt Converted to Equity at a Premium Phase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed

19 Mar 2024 Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced

06 Mar 2024 Cingulate to Attend DCAT Week 2024 in New York City

Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform

Sign-up for Email Alerts

Required fields denoted by an asterisk ().

Alert type
Quote
SEC Filing
Event
News
Weekly Summary

Contact IR

Thomas Dalton
Head of Investor & Public Relations
(913) 942-2301
IR@cingulate.com

Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.